| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Douglas Love
Also a director
PRESIDENT AND CEO
Title from the Form 4 dated Sep 24, 2026
|
58 | Not stated | $3,579,202 | |
|
Jennifer Lew
Executive Vice President and Chief Financial Officer
|
Not stated |
Since 2019
7 years
|
$1,341,274 | |
|
Rick Artis
Executive Vice President and Chief Scientific Officer
|
Not stated |
Since 2023
3 years
|
Not reported | |
|
Ted Yednock
Chief Innovation Officer
|
Not stated |
Since 2021
5 years
|
$1,379,052 | |
|
Michael Overdorf
Executive Vice President and Chief Business Officer
|
Not stated |
Since 2020
6 years
|
Not reported | |
|
Jamie Dananberg
Executive Vice President and Chief Medical Officer
|
Not stated |
Since 2023
3 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Aug 10, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Douglas Love
CEO
|
58 |
2014
12 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Bettina M. Cockroft
|
59 |
2022
4 years
|
Not stated |
Audit Committee
|
CNS Pharmaceuticals, Inc. | $162,215 | |
|
William H. Carson, M.D.
|
67 |
2021
5 years
|
Not stated | None stated | None stated | $164,215 | |
|
William (BJ) Jones, Jr.
|
62 |
2025
1 year
|
Not stated | None stated | Apogee Therapeutics, Inc. | $475,989 | |
|
Jung E. Choi
|
56 |
2020
6 years
|
Not stated | None stated | None stated | $164,215 | |
|
William D. Waddill
|
69 |
2021
5 years
|
Not stated |
Audit Committee · Chair
|
Arrowhead Pharmaceuticals, Inc. | $171,215 | |
|
Mark S. Blumenkranz, M.D., M.S.S.
Joined Aug 10, 2026
|
- | - | - |
Audit Committee
Science and Technology committee
|
- | - | |
|
Thomas G. Wiggans
Leaving at the meeting
Board chair
|
Not stated | Not stated | Not stated | None stated | None stated | $192,215 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...